Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients - Wikidata - awgldk - TriplyDB

Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients

Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients

http://www.wikidata.org/entity/Q34045233

about

Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?Quality of outcome reporting in phase II studies in pulmonary tuberculosis Nitroimidazoles for the treatment of TB: past, present and future Rising to the challenge: new therapies for tuberculosis Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis Pharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosis A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)Pipeline of drugs for related diseases: tuberculosis Tuberculosis therapy for 2016 and beyond.Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.Recent advances in tuberculosis: New drugs and treatment regimens.Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action.Exploring prospects of novel drugs for tuberculosis.Early Bactericidal Activity of AZD5847 in Patients with Pulmonary Tuberculosis.Novel regimens identified in mice for treatment of latent tuberculosis infection in contacts of patients with multidrug-resistant tuberculosis Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infections Time to detection of Mycobacterium tuberculosis as an alternative to quantitative cultures.Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.Comparative bioactivation of the novel anti-tuberculosis agent PA-824 in Mycobacteria and a subcellular fraction of human liver.PA-824 exhibits time-dependent activity in a murine model of tuberculosis.Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis.Bactericidal activity of PA-824 against Mycobacterium tuberculosis under anaerobic conditions and computational analysis of its novel analogues against mutant Ddn receptor Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((s)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824).Impact of Fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824.New regimens for reducing the duration of the treatment of drug-susceptible pulmonary tuberculosis.Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis Tuberculosis drug development: ensuring people living with HIV are not left behind.Phase II dose-ranging trial of the early bactericidal activity of PA-824 Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating Mycobacterium tuberculosis.TB and HIV Therapeutics: Pharmacology Research Priorities.Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen Evaluation of pharmacokinetic interaction between PA-824 and midazolam in healthy adult subjects.The chemotherapy of tuberculosis: past, present and future.Effect of a high-calorie, high-fat meal on the bioavailability and pharmacokinetics of PA-824 in healthy adult subjects.Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners.Tuberculosis drugs: new candidates and how to find more.Models and approaches for anti-TB drug testing.Challenges and opportunities in developing novel drugs for TB.New treatment options for multidrug-resistant tuberculosis.

P2860

Q26771997-F65AAE20-7965-4E30-A4E9-AA32C3800FFF Q26777160-4C8A54C6-EC47-4FFA-AB92-3FB3082967AA Q26849554-E3E5700D-19BC-4B2B-A910-434DCA80DB5B Q27011672-F35BB329-6546-485C-B5D7-F6FE8B9BEFC5 Q28537839-E48D87F8-5E19-42A4-8D9E-45BD5EB087DC Q28542435-0CDBDC03-97B2-440F-BB1D-E6177E1E58DE Q28602112-B354B268-E0DF-4297-B1C7-9072B9F581E9 Q28818217-86C7D73A-4978-462C-9621-48ABBE20437A Q30248788-CF37CE18-0999-4D9F-A757-6840322FE9F1 Q30352594-35E169BA-2418-40E1-8C5B-C1BBD759F387 Q30360811-0681AB35-4693-4BF6-9EB1-36E2D1CEAB6E Q30419537-CE6B26AD-5969-4D02-9153-8A2D1130F595 Q30421213-5EAEAF39-AA0F-4536-BE2C-1239223DF8B4 Q33434791-E55DCC14-C173-4B26-8C3B-412AAF6F824D Q33623003-94F82BC6-EC25-4B2D-A8EB-16192CA7CD3C Q33767602-4E3C89EB-2D65-4D44-8007-0F26B06DC367 Q33941934-8B7566C1-9A19-4A2D-95F8-EEE30C466DD4 Q34057466-AEA52479-0C98-45F4-BE69-42942792EAF8 Q34449746-CDF8F2FC-D06D-4B70-A9CF-FE44FA9D85C1 Q34483632-C0FC0282-1963-46C1-B32C-FFF3542AA06A Q34922056-D8469D92-4E82-4537-93A3-42A7B54E7BEB Q35003633-72F83608-0DAB-46DC-A3F2-C9D1EC335E65 Q35171238-AEC7F8A6-C60B-4033-959E-CB2C56DC0A2C Q35598383-6D6CE1A7-5C1E-4187-9613-8729DD19CB49 Q35676180-58C6064D-C406-47F1-8FBD-5C19210E52BC Q35960987-72460A3D-D548-4D59-90FE-789846794B05 Q35991204-62896423-66ED-47E5-9C1C-0C7A769EB727 Q36018781-A5DFE98C-E350-4410-839E-284FA11FEDFF Q36092172-60E70FD3-3754-413A-8687-A9DBED0EE706 Q36099838-5EE5C02F-F59F-447B-A9B8-10378D420DEF Q36236341-299601E7-02E5-491D-BE01-C3EAF4568160 Q37036499-E3C6967F-6421-4C57-B3FC-0BDD6E752916 Q37036606-B4D7D60A-7373-4BC4-BDFA-CA37CA64600B Q37076746-BA25A41E-0A31-484B-87C2-E2BD8E636E4E Q37263381-C0B4ECA9-1ED3-4E8E-AE87-06D4A55027B1 Q37335803-7E73897D-92D8-4B5D-A299-65B10B394F2D Q37894691-3406D156-2087-49C3-8A91-DEF35A11D334 Q37910251-D83FBEF5-44C2-4661-8974-132DAAB0AEB8 Q37924294-83A47053-8BE3-4F19-A4E2-A0F5B1363D2F Q38024041-E9AFC0A3-0CD2-4D1E-94F0-883A01CC4627

P2860

Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients

http://www.wikidata.org/entity/Q34045233

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Early bactericidal activity an ...... positive tuberculosis patients

@ast

Early bactericidal activity an ...... positive tuberculosis patients

@en

Early bactericidal activity an ...... positive tuberculosis patients

@nl

type

label

Early bactericidal activity an ...... positive tuberculosis patients

@ast

Early bactericidal activity an ...... positive tuberculosis patients

@en

Early bactericidal activity an ...... positive tuberculosis patients

@nl

prefLabel

Early bactericidal activity an ...... positive tuberculosis patients

@ast

Early bactericidal activity an ...... positive tuberculosis patients

@en

Early bactericidal activity an ...... positive tuberculosis patients

@nl

P1433

Q34045233-22A2C9D8-CF59-4720-934C-0D2E57C49541

P1476

Q34045233-9438FDD9-9365-48DA-A4E9-4F658FC1DA66

P2093

Q34045233-04A270CC-2270-4553-9397-B5847E9AAF1C

Q34045233-26658F02-60D4-4EE8-93B7-E848369D0306

Q34045233-302F9AD4-216C-43E1-AE40-3CCF8013455A

Q34045233-3B02EA0C-6881-41AB-8C3E-319B0F7808E1

Q34045233-6DDC3087-8EC5-415D-9BBB-675E08D896AA

Q34045233-6E74B9A6-C70C-4AEE-BEC8-3468DBB6C36B

Q34045233-92A0E8A5-AE06-4880-82EB-E2A6EEF4C2E1

Q34045233-95D5695F-EF57-4EA6-8EB3-6C4E0F242601

Q34045233-A7CB9B58-1124-4BDC-9C3A-BF9480B9B63E

Q34045233-ADE003C5-C375-461D-8C92-C0B24BB76C93

P2860

Q34045233-0CD4BC15-4BCC-46CD-9AED-B3E40C5E38B3

Q34045233-111D675E-6127-4EFF-809C-6D9608F5A7CD

Q34045233-1D914299-472B-47F6-9B3B-9D6E4BABA86F

Q34045233-403E2D38-91D5-4818-884B-9AC36A24929D

Q34045233-4CD3C938-B2DB-4C93-8D2A-0F064CDA017C

Q34045233-580458B8-BC56-4CF6-B06F-B67A423AD554

Q34045233-61EAE196-1479-4DFC-977A-CCA9A58DFDE1

Q34045233-863AF33B-7E25-4457-A5F8-CD14C104E9FB

Q34045233-A9F17A9C-1FB3-499E-92B8-5DDB94DE43C2

Q34045233-AE8B7614-918B-46E6-B5D7-F51374348162

P304

Q34045233-A176A897-0CB5-456C-A8D9-4E1B2996E6EF

P31

Q34045233-D973E902-8371-42DB-A167-B8D6C5FCD0B9

P356

Q34045233-DF935E4C-47E3-473D-8A3C-5BD92B7566AF

P407

Q34045233-56DF5846-A080-41D4-8574-D1BF3677F543

P433

Q34045233-C8A4D211-8565-4CAF-A1A0-D7D0142223E7

P478

Q34045233-1A0B890A-2F9F-4F5E-9752-A083B4243E47

P577

Q34045233-DA87E65C-8F51-4727-B743-D46E1B3FD18A

P698

Q34045233-4F03A0FA-7B2D-458F-B8AF-93B14976A5BF

P921

Q34045233-E596DF5A-3B84-4A3C-9106-02DC33E6B784

Q34045233-E5DB4D69-0085-49ED-A060-0DE1963084C3

P932

Q34045233-7A50E564-9A4C-42C5-A7E9-59DC455E0E82

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Early bactericidal activity an ...... positive tuberculosis patients

@en

P2093

Amour Venter

http://www.w3.org/2001/XMLSchema#string

Andreas H Diacon

http://www.w3.org/2001/XMLSchema#string

Ann M Ginsberg

http://www.w3.org/2001/XMLSchema#string

Christo van Niekerk

http://www.w3.org/2001/XMLSchema#string

Doris J Rouse

http://www.w3.org/2001/XMLSchema#string

Karl Whitney

http://www.w3.org/2001/XMLSchema#string

Kim Narunsky

http://www.w3.org/2001/XMLSchema#string

Madeleine Hanekom

http://www.w3.org/2001/XMLSchema#string

Martino W Laurenzi

http://www.w3.org/2001/XMLSchema#string

Melvin K Spigelman

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects

PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release

Mycobacterium tuberculosis from chronic murine infections that grows in liquid but not on solid medium

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

The diarylquinoline TMC207 for multidrug-resistant tuberculosis

Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models.

Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis.

Early bactericidal activity of antituberculosis agents.

Predictive in vitro models of the sterilizing activity of anti-tuberculosis drugs.

Comparison of mycobacteria growth indicator tube with BACTEC 460 for detection and recovery of mycobacteria from clinical specimens.

P304

3402-3407

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01354-09

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20498324

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

2916303

http://www.w3.org/2001/XMLSchema#string